NeuroBion Tablets
- Manufacturer
- BENARD INDUSTRIES INC | Pharbest Pharmaceuticals, Inc.
- Effective date
- 2015-10-30
- Label type
- DIETARY SUPPLEMENT
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:48:09
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
STATEMENT OF IDENTITY SECTION
| Supplement Facts Serving Size : 1 tablet Servings per Container : 50 | ||
| Amount per Tablet | % Daily Value* | |
| Vitamin B-1 (as Thiamine HCl) | 100 mg. | 6667% |
| Vitamin B-6 (as Pyridoxine HCl) | 100 mg. | 5000% |
| Vitamin B-12 (as Cyanocobalamin) | 200 mcg. | 3333% |
| *% Daily value based on a 2,000 calorie diet |
Other Ingredients: Calcium Carbonate, Dicalcium Phosphate, Microcrystalline Cellulose, Hydroxypropyl Methylcellulose, Triacetin, Stearic Acid, Magnesium Stearate, Croscarmellose Sodium, Silica, Maltodextrin, Propylene Glycol, Titanium Dioxide.
WARNINGS SECTION
KEEP OUT OF REACH OF CHILDREN
PRECAUTIONS SECTION
CAUTION: Tamper evident seal under bottle cap. Do not use if seal is broken.
SAFE HANDLING WARNING SECTION
Keep tightly closed in a dry place at controlled temperature 59°-86° F (15°-30°C)
DOSAGE & ADMINISTRATION SECTION
Suggested Use: As a dietary supplement, take one tablet daily.
HEALTH CLAIM SECTION
HIGH POTENCY FORMULA
CLASSIC FORMULATM
DIETARY SUPPLEMENT
EXCELLENCE IN NUTRITION
Design: © OTC Pharmaceutical Products
QUESTIONS 1.800.595.0480
Distributed by:
OTC Pharmaceutical Products
10860 NW 27th St. Miami, FL 33172
Packaging
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| CYANOCOBALAMIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| PYRIDOXINE Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20170310 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| cf050ccd-1144-f76a-e00d-e5698d8597d4 | Product name | 6 | 20250625 |
| 59361619-24d9-b610-eca6-5a7f25ed5e03 | Product name | 5 | 20240909 |
| b82b4008-22fd-05f5-6cc6-c0a6e81c65b8 | Product name | 2 | 20240805 |
| d206bb34-ea65-399d-70d9-834f22dc2c18 | Product name | 3 | 20170724 |
| 5e18e798-5614-cf5c-0185-38b1cb77a093 | Product name | 2 | 20160822 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55959-117-05 | NeuroBion | 1 in 1 CARTON | TABLET | 1 | 1 | |
| 55959-117-05 | NeuroBion | 50 in 1 BOTTLE | TABLET | 50 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CYANOCOBALAMIN | ACTIVE INGREDIENT | P6YC3EG204 | 1 | |
| PYRIDOXINE HYDROCHLORIDE | ACTIVE INGREDIENT | 68Y4CF58BV | 1 | |
| THIAMINE HYDROCHLORIDE | ACTIVE INGREDIENT | M572600E5P | 1 | |
| CYANOCOBALAMIN | ACTIVE MOIETY | P6YC3EG204 | 1 | |
| PYRIDOXINE | ACTIVE MOIETY | KV2JZ1BI6Z | 1 | |
| THIAMINE ION | ACTIVE MOIETY | 4ABT0J945J | 1 | |
| CALCIUM CARBONATE | INACTIVE INGREDIENT | H0G9379FGK | 1 | |
| CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS | INACTIVE INGREDIENT | L11K75P92J | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| HYPROMELLOSE 2910 (15 MPA.S) | INACTIVE INGREDIENT | 36SFW2JZ0W | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| MALTODEXTRIN | INACTIVE INGREDIENT | 7CVR7L4A2D | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| TRIACETIN | INACTIVE INGREDIENT | XHX3C3X673 | 1 |
Products#
Every source-derived product name is available through these pages.
- NeuroBion
- THIAMINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE, CYANOCOBALAMIN
- THIAMINE HYDROCHLORIDE
- THIAMINE ION
- PYRIDOXINE HYDROCHLORIDE
- PYRIDOXINE
- CYANOCOBALAMIN
- CALCIUM CARBONATE
- CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
- CELLULOSE, MICROCRYSTALLINE
- HYPROMELLOSE 2910 (15 MPA.S)
- TRIACETIN
- STEARIC ACID
- MAGNESIUM STEARATE
- CROSCARMELLOSE SODIUM
- SILICON DIOXIDE
- MALTODEXTRIN
- PROPYLENE GLYCOL
- TITANIUM DIOXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 55959-117 | 55959-117-05 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / TOPICAL | 8 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, EXTENDED RELEASE / ORAL | 5119 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | PELLET / ORAL | 1140 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | POWDER, FOR SUSPENSION / ORAL | 11.25 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | CAPSULE, DELAYED RELEASE / ORAL | 5.1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| HYPROMELLOSE 2910 (15 MPA.S) | HYPROMELLOSE 2910 (15 MPA.S) | 36SFW2JZ0W | CAPSULE / ORAL | 70 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| MALTODEXTRIN | MALTODEXTRIN | 7CVR7L4A2D | FILM, SOLUBLE / ORAL | 19 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, DELAYED RELEASE / ORAL | 2210 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| MALTODEXTRIN | MALTODEXTRIN | 7CVR7L4A2D | TABLET, CHEWABLE / ORAL | 292 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| HYPROMELLOSE 2910 (15 MPA.S) | HYPROMELLOSE 2910 (15 MPA.S) | 36SFW2JZ0W | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 15 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SUSPENSION / ORAL | 4441 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION, EXTENDED RELEASE / ORAL | 1120 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | SUSPENSION / ORAL | 7 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | JELLY / TOPICAL | 20 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | TABLET, FILM COATED / ORAL | 15.12 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET / ORAL | 64 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / OPHTHALMIC | 0.6 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 11 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYRUP / ORAL | 5700 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, FILM COATED / ORAL | 330 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, CHEWABLE / ORAL | 180 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / ORAL | 27120 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | IMPLANT / SUBCUTANEOUS | 1.04 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CONCENTRATE / ORAL | 7000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / ORAL | 2240 mg | ||
| CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | POWDER / SUBLINGUAL | 30 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, EXTENDED RELEASE / ORAL | 392 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | REMEDYREPACK INC. | 0f38c4ba-cebf-49f4-b0a6-8a5d3ebf618c | 2026-08-31 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 764d608a-d821-4447-85e1-6af297abb4c1 | 2026-07-31 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| thiamine hydrochloride | THIAMINE HYDROCHLORIDE | Sagent Pharmaceuticals | 5982cf83-01d6-4acb-8373-339079b8a76e | 2026-07-22 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | c3c9db74-95d4-487c-90c3-c810786fbaec | 2026-01-14 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | ca4899c6-cea1-48d6-b0ae-9efcf67f6fcb | 2026-01-13 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | af3f9344-f743-4bad-b319-53b96e13fee2 | 2026-01-09 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | ONESOURCE SPECIALTY PHARMA LIMITED | 2e957a35-83b3-47f5-ad09-216b22cc30be | 2025-11-20 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| THIAMINE HYDROCHLORIDE | THIAMINE HYDROCHLORIDE | Henry Schein, Inc. | 3bdf3b03-90cf-4416-9344-7733b193adf5 | 2025-11-07 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Eugia US LLC | 4985bf3c-abe5-4bbb-9dcc-6de387d36d6b | 2025-10-23 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| THIAMINE HYDROCHLORIDE | THIAMINE HYDROCHLORIDE | Henry Schein, Inc. | c006eca3-137a-493f-bbc4-f04e463d66f9 | 2025-09-26 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Fosun Pharma USA Inc. | 3649f7b5-dcce-b246-e063-6394a90a3145 | 2025-06-19 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| thiamine hydrochloride | THIAMINE HYDROCHLORIDE | Gland Pharma Limited | fc0265cd-d13a-477c-8c2c-8d44fd86444e | 2025-02-27 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Camber Pharmaceuticals, Inc. | 2d402a31-3240-42a0-bd34-8fccd6a792d3 | 2025-02-03 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | Caplin Steriles Limited | 8909424c-9d5b-4e35-b2d3-da9d3316a4cc | 2024-05-20 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 63f3631b-ba1e-430c-a30b-dd05b2c00c13 | 2024-04-11 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | Armas Pharmaceuticals Inc. | 9ecbf165-bd2e-4bc1-a52c-1f40d1c2bbd9 | 2023-05-22 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine | THIAMINE HYDROCHLORIDE | NorthStar Rx LLC | f4790075-a740-4550-9d4c-69a00dac354c | 2023-04-20 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Dr. Reddy's Laboratories Inc. | 43926cec-e483-8cf1-4d8d-5145e554d45d | 2022-12-30 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
| Thiamine Hydrochloride | THIAMINE HYDROCHLORIDE | Mylan Institutional LLC | 12986d0e-b8bf-4338-9d85-07f973b35439 | 2021-04-15 | Warnings, Adverse reactions | THIAMINE HYDROCHLORIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
